Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 12, 2015

Primary Completion Date

August 19, 2016

Study Completion Date

August 19, 2016

Conditions
Solid Tumors
Interventions
DRUG

lurbinectedin (PM01183)

Trial Locations (16)

14004

Complejo Hospitalario Regional Reina Sofía, Córdoba

15706

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

28222

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

29010

Complejo Hospitalario de Especialidades Virgen de La Victoria, Málaga

46026

Hospital Universitari I Politècnic La Fe, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

Cancer Therapy & Research Center, San Antonio

80045

University of Colorado Cancer Center, Aurora

90403

Sarcoma Oncology Research Center, Santa Monica

280035

Hospital Universitario 12 de Octubre, Madrid

02215

Dana Farber Cancer lnstitute, Boston

08035

Hospital Universitari Vall D'Hebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaMar

INDUSTRY